QurAlis’ selective Kv7 opener, a drug candidate for ALS, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to Retigabine in preclinical models
Frontier Medicines and AbbVie establish global partnership to discover and develop novel therapies and E3 degraders against difficult-to-drug targets
